{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:34:35Z","timestamp":1791513275598,"version":"4.3.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.eururo.2025.05.005","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T15:35:47Z","timestamp":1747236947000},"page":"228-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Management Dilemma for Very High-risk Non\u2013muscle-invasive Bladder Cancer: Real-World Data Challenge the Guideline Recommendation for Upfront Radical Cystectomy"],"prefix":"10.1016","volume":"88","author":[{"given":"Jos\u00e9 Daniel","family":"Subiela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Scilipoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Contieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nijati","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.05.005_b0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology guidelines on non\u2013muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014a summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.05.005_b0010","doi-asserted-by":"crossref","unstructured":"Scilipoti P, Longoni M, de Angelis M, et al. Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer. BJU Int. In press. https:\/\/doi.org\/10.1111\/bju.16675.","DOI":"10.1111\/bju.16675"},{"key":"10.1016\/j.eururo.2025.05.005_b0015","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non\u2013muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.05.005_b0020","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.euo.2021.11.006","article-title":"Updated European Association of Urology (EAU) prognostic factor risk groups overestimate the risk of progression in patients with non\u2013muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.05.005_b0025","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.euo.2023.07.012","article-title":"Oncological outcomes for patients with European Association of Urology very high-risk non\u2013muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin or early radical cystectomy","volume":"6","author":"Contieri","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.05.005_b0030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/bco2.305","article-title":"Validation of non\u2013muscle-invasive bladder cancer risk stratification updated in the 2021 European Association of Urology guidelines","volume":"5","author":"Miyake","year":"2024","journal-title":"BJUI Compass"},{"key":"10.1016\/j.eururo.2025.05.005_b0035","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.euo.2024.01.017","article-title":"Unlocking the potential of adequate bacillus Calmette-Gu\u00e9rin immunotherapy in very-high-risk non\u2013muscle-invasive bladder carcinoma: a multicenter analysis of oncological outcomes and risk dynamics","volume":"7","author":"Subiela","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.05.005_b0040","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.20.01665","article-title":"Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-Feasibility study","volume":"39","author":"Catto","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.05.005_b0045","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/bjc.2014.633","article-title":"Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients","volume":"112","author":"Orsola","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2025.05.005_b0050","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.urolonc.2018.03.018","article-title":"A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancer","volume":"36","author":"Mari","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.05.005_b0055","doi-asserted-by":"crossref","first-page":"275.e1","DOI":"10.1016\/j.urolonc.2022.02.004","article-title":"Histological variants of non-muscle invasive bladder cancer: survival outcomes of radical cystectomy vs. bladder preservation therapy","volume":"40","author":"Dursun","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.05.005_b0060","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3233\/BLC-200404","article-title":"Revisiting an old conundrum: a systematic review and meta-analysis of intravesical therapy for treatment of urothelial carcinoma of the prostate","volume":"7","author":"Kokorovic","year":"2021","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2025.05.005_b0065","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s00345-018-2299-2","article-title":"Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought","volume":"36","author":"Palou","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.05.005_b0070","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.euo.2024.09.016","article-title":"Minimal residual disease detection with urine-derived DNA is prognostic for recurrence-free survival in bacillus Calmette-Gu\u00e9rin\u2013unresponsive non\u2013muscle-invasive bladder cancer treated with nadofaragene firadenovec","volume":"8","author":"Narayan","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.05.005_b0075","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825002830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825002830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T12:12:15Z","timestamp":1755087135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825002830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0302283825002830"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.05.005","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management Dilemma for Very High-risk Non\u2013muscle-invasive Bladder Cancer: Real-World Data Challenge the Guideline Recommendation for Upfront Radical Cystectomy","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}